Biostar Pharmaceuticals EBIT

Biostar Pharmaceuticals (BSPM) currently reports a EBIT of $3.6M as of September 2017. That compares with $-30M in the prior-year period — up 111.7% year over year. That is below the sector sector average of $2.6T. Use the charts on this page to explore Biostar Pharmaceuticals's EBIT history and peer comparisons.

Biostar Pharmaceuticals's EBIT increased from $-30M to $3.6M — a 111.7% year-over-year increase (period ending September 2017). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Biostar Pharmaceuticals's EBIT of $3.6M is lower than the its sector sector average of $2.6T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Biostar Pharmaceuticals reported $3.6M in EBIT as of September 2017. That compares with $-30M in the prior-year period — up 111.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $3.6M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $2.6T. From there, open related valuation or income-statement pages for Biostar Pharmaceuticals, and consider following BSPM for alerts when major investors trade the stock.